Cytoreductive surgery for hepatocellular carcinoma

Area of Science:

• Hepatobiliary Surgery
• Surgical Oncology
• Gastroenterology

Background:

• Inoperable hepatocellular carcinoma presents significant treatment challenges.
• Cytoreductive surgery aims to improve survival and quality of life in advanced cancers.
• Evaluating the efficacy of cytoreductive surgery versus systemic chemotherapy is crucial.

Purpose of the Study:

• To assess the survival outcomes and quality of life following cytoreductive surgery for inoperable hepatocellular carcinoma.
• To compare the effectiveness of cytoreductive surgery with systemic chemotherapy.
• To determine the contribution of additional treatments to survival benefit.

Main Methods:

• Prospective study of 26 patients with inoperable hepatocellular carcinoma undergoing cytoreductive surgery.
• Cytoreduction techniques included liver resection, cryosurgery, microwave tissue coagulation, and/or absolute alcohol injection.
• Comparison with 26 matched patients receiving systemic chemotherapy.

Main Results:

• In-hospital mortality was 7.7%, with excellent symptomatic relief and quality of survival.
• Median survival after cytoreduction was 10.0 months, significantly better than the chemotherapy group (P = 0.0001).
• No significant difference in survival was observed between patients receiving additional treatments and those who did not.

Conclusions:

• Cytoreductive surgery offers a survival advantage for inoperable hepatocellular carcinoma patients.
• The primary survival benefit appears to stem from the cytoreductive surgery itself.
• Further research may explore optimizing cytoreductive techniques and patient selection.